Latest news with #MarketForecast
Globe and Mail
3 hours ago
- Health
- Globe and Mail
PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company
The Key Ascites Companies in the market include - PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others. DelveInsight's 'Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Ascites Market Report: The Ascites market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In November 2024, Pharmanovia, an international pharmaceutical company specializing in commercializing innovative therapies and enhancing the lifecycle of established medicines, announced the expansion of its oncology portfolio through a new licensing agreement for catumaxomab, aimed at treating malignant ascites. In 2023, the US ascites market size attributed to cirrhosis was valued at over USD 800 million, with projections indicating growth throughout the forecast period (2024–2034). In 2023, the market size for diuretics used in the treatment of ascites caused by cirrhosis in the US was estimated to be approximately USD 140 million. In 2023, the US had the highest number of ascites cases caused by cirrhosis among the 7MM, exceeding 152,000 cases. This figure is expected to rise throughout the forecast period (2024-2034). In 2023, breast cancer contributed the highest number of ascites cases caused by malignancies in the US, with approximately 13,000 cases, followed by colorectal cancer. In the US, severity-specific cases of Grade II and III ascites totaled approximately 125,000 in 2023. Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others The Ascites market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics. Ascites Overview A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. Ascites may be painful in extreme cases. Get a Free sample for the Ascites Market Report Ascites Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Ascites Epidemiology Segmentation: The Ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast Ascites Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Ascites Therapies and Key Companies Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market Ascites Market Strengths The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase in the patient population of ascites Ascites Market Opportunities Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies Scope of the Ascites Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies Ascites Market Dynamics: Ascites market drivers and Ascites market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. Ascites Market Report Introduction 2. Executive Summary for Ascites 3. SWOT analysis of Ascites 4. Ascites Patient Share (%) Overview at a Glance 5. Ascites Market Overview at a Glance 6. Ascites Disease Background and Overview 7. Ascites Epidemiology and Patient Population 8. Country-Specific Patient Population of Ascites 9. Ascites Current Treatment and Medical Practices 10. Ascites Unmet Needs 11. Ascites Emerging Therapies 12. Ascites Market Outlook 13. Country-Wise Ascites Market Analysis (2020–2034) 14. Ascites Market Access and Reimbursement of Therapies 15. Ascites Market Drivers 16. Ascites Market Barriers 17. Ascites Appendix 18. Ascites Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
5 days ago
- Business
- Globe and Mail
Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon
The Key Cancer Vaccines Companies in the market include - Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others. DelveInsight's 'Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cancer Vaccines Market Report: The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01. In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries. In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines. In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments. In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000. Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK. The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more. Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics. Cancer Vaccines Overview Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence. Cancer Vaccines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cancer Vaccines Epidemiology Segmentation: The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Cancer Vaccines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cancer Vaccines Therapies and Key Companies Cancer Vaccines Market Strengths Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market Cancer Vaccines Market Opportunities Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime Scope of the Cancer Vaccines Market Report Table of Contents 1. Cancer Vaccines Market Report Introduction 2. Executive Summary for Cancer Vaccines 3. SWOT analysis of Cancer Vaccines 4. Cancer Vaccines Patient Share (%) Overview at a Glance 5. Cancer Vaccines Market Overview at a Glance 6. Cancer Vaccines Disease Background and Overview 7. Cancer Vaccines Epidemiology and Patient Population 8. Country-Specific Patient Population of Cancer Vaccines 9. Cancer Vaccines Current Treatment and Medical Practices 10. Cancer Vaccines Unmet Needs 11. Cancer Vaccines Emerging Therapies 12. Cancer Vaccines Market Outlook 13. Country-Wise Cancer Vaccines Market Analysis (2020–2034) 14. Cancer Vaccines Market Access and Reimbursement of Therapies 15. Cancer Vaccines Market Drivers 16. Cancer Vaccines Market Barriers 17. Cancer Vaccines Appendix 18. Cancer Vaccines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
04-08-2025
- Business
- Yahoo
AI SDR Market $15.01 billion by 2030
DELRAY BEACH, Fla., Aug. 4, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the global AI SDR Market size is projected to reach USD 15.01 billion by 2030 from USD 4.12 billion in 2025, at a CAGR of 29.5% during the forecast period. Browse in-depth TOC on "AI SDR Market" 320 – Tables65 - Figures350 – Pages Download PDF Brochure @ Scope of the Report Report Metrics Details Market Size Available for Years 2020–2030 Base Year Considered 2024 Forecast Period 2025–2030 Forecast Units USD Billion Segments Covered Offering, Deployment Model, Sales Channel, Use Case, End User, And Region Geographies Covered North America, Europe, Asia Pacific, Middle East & Africa, and Latin America Companies Covered HubSpot (US), Salesforce (US), Dialpad (US), Salesloft (US), 6Sense (US), ZoomInfo (US), (US), OpenAI (US), Clari (US), Cognism (UK), Microsoft (US), GupShup (US), Outreach (US), Vidyard (Canada), Plivo (US), Qualified (US), (US), Conversica (US), Klenty (India), (US), (US), Waalaxy (France), Common Room (US), Artisan AI (US), UserGems (US), Scratchpad (US), Clay (US), Unify (Germany), Lyzr AI (US), Humantic AI (US), Relevance AI (Australia), (US), Salesforge (Estonia), 11x AI (UK), Floworks (US), Warmly (US), Luru (US), AiSDR (US), Bluebirds (US), ChaseLabs (UK), (US), SuperAGI (US), Instantly (US), Persana AI (US), (US), and Saleshandy (India) The adoption of human-AI engagement models is enabling sales teams to balance automation with personalized interactions, improving overall efficiency. Intent-based prospecting is another key factor, helping organizations identify high-value leads through behavioral signals and predictive analytics. Additionally, the ability to deliver personalization at scale is transforming outbound efforts, allowing SDRs to engage large volumes of prospects with tailored messaging, driving stronger conversion rates, and accelerating top-of-funnel performance. Request Sample Pages@ Lead generation & qualification will register the largest market share during the forecast period Generating and qualifying leads to the core focus of AI SDR adoption, as companies seek to improve pipeline efficiency and conversion outcomes. AI systems analyze large datasets to identify high-fit prospects, enrich contact information, and score leads based on intent and engagement signals. This reduces manual effort while enabling SDRs to prioritize outreach more effectively. With consistent pressure to accelerate revenue cycles, lead generation and qualification continue to dominate use case investment across AI-driven sales development workflows. Healthcare & life sciences is poised for the fastest growth during the forecast period Healthcare and life sciences are experiencing the highest growth rate in the AI SDR Market due to rising demand for precision outreach in highly regulated, information-intensive sales cycles. AI SDR tools help streamline prospecting across hospitals, clinics, and research institutions by automating lead qualification and delivering compliant, personalized communication. As the sector increasingly adopts digital engagement models, AI-driven sales development enables faster rep access to decision-makers, accelerating pipeline generation and reducing manual effort. Inquire Before Buying@ North America will account for the largest market during the forecast period North America holds the largest market share in the AI SDR landscape, supported by high enterprise adoption, advanced CRM ecosystems, and strong demand for sales automation. Vendors such as Outreach and Salesloft play a pivotal role by offering AI-driven tools that streamline prospecting, lead scoring, and engagement. The region's mature digital infrastructure and emphasis on data-driven sales execution continue to drive widespread deployment of scalable AI SDR platforms. Top Key Companies in AI SDR Market: The major players in the AI SDR Market include HubSpot (US), Salesforce (US), 11x AI (UK), Artisan AI (US), Luru (US), AiSDR (US), Lyzr AI (US), Floworks (US), Common Room (US), Salesforge (Estonia), and Qualified (US). Browse Adjacent Markets: Artificial Intelligence (AI) Market Research Reports & Consulting Related Reports: Deepfake AI Market - Global Forecast to 2031 Customer Data Platform Market - Global Forecast to 2030 Artificial Intelligence Market - Global Forecast to 2032 AI in Finance Market - Global Forecast to 2030 AI for Sales and Marketing Market - Global Forecast to 2030 Get access to the latest updates on AI SDR Companies and AI SDR Industry About MarketsandMarkets™ MarketsandMarkets™ has beesn recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets
Globe and Mail
31-07-2025
- Business
- Globe and Mail
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
Merkel Cell Carcinoma Market Forecast, combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM. The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others. DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034 Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France. Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends. The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM. According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor. Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis Recent Developments: In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others. In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC. In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary. In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery. The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA). The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells. DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others. Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape. MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth. Table of Contents 1. Key Insights 2. Report Introduction 3. Merkel Cell Carcinoma Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Merkel Cell Carcinoma Background and Overview 7. Merkel Cell Carcinoma Epidemiology and Market Methodology 8. Epidemiology and Merkel Cell Carcinoma Patient Population 9. Merkel Cell Carcinoma Patient Journey 10. Merkel Cell Carcinoma Marketed Therapies 11. Merkel Cell Carcinoma Emerging Drug Profiles 12. MCC: Market Analysis 13. Key Opinion Leaders' Views 14. Merkel Cell Carcinoma Unmet Needs 15. Merkel Cell Carcinoma SWOT Analysis 16. Merkel Cell Carcinoma Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Merkel Cell Carcinoma Pipeline Insight Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others. About DelveInsight DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Associated Press
21-07-2025
- Business
- Associated Press
Growing Adoption of Cloud and Integration of AI/ML into Endpoint Security Solutions Fueling Opportunities
DUBLIN--(BUSINESS WIRE)--Jul 21, 2025-- The 'Endpoint Security Market by Solution, Service, Enforcement Point, Vertical, Region - Global Forecast to 2030" report has been added to offering. The global endpoint security market size is projected to grow from USD 27.46 billion in 2025 to USD 38.28 billion by 2030 at a Compound Annual Growth Rate (CAGR) of 6.3%. The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall endpoint security market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities. Organizations are increasingly aware of the risks of internal misuse of entitlement, whether on purpose or inadvertently, with remote work architectures, third-party access, and hybrid IT prevalent. The potential for excessive user privileges or poorly managed user privileges is likely to be greater than ever. Endpoint privilege management is able to mitigate this issue by applying the principle of least privilege, meaning users have the minimum permission that they require, when required. This approach decreases the potential attack surface, decreases lateral movement risk, and mitigates inappropriate access to data. Given the requirement for strong privilege controls in regulated industries such as BFSI, healthcare, and IT services, strong privilege controls in any endpoint security policy are now table stakes for any successful policy. The key players in the endpoint security market include Microsoft (US), Palo Alto (US), SentinelOne (US), Trend Micro (Japan), Fortinet (US), Cisco (US), Check Point (Israel), Blackberry (Canada), ESET (Slovakia), Kaspersky (Russia), Trellix (US), CrowdStrike (US), IBM (US), Broadcom (US), Sophos (UK), and others. By vertical, the BFSI segment accounts for the largest market share during the forecast period. Endpoint security is very important for BFSI organizations, which involve a considerable amount of sensitive financial and personal information. It is all about protecting all devices connected to the network, such as laptops, mobile devices, ATMs, and point-of-sale terminals, from unauthorized access and threats. Endpoint security involves modern tools, threat detection, malware and protection, encryption, and access control to secure endpoints. In December 2022 alone, finance and insurance organizations across the world suffered 566 breaches that resulted in over 254 million records being leaked. In January 2024, LoanDepot was breached, with the impact of 16.9 million individuals' security being compromised, including sensitive personal and financial data. Evolve Bank & Trust reported a breach in security that compromised the security of 7.6 million people, including social security numbers and account information. By developing and investing in endpoint security solutions that include real-time detection, protecting customer information to uphold trust, and strategic investment to sustain customers, BFSI organizations are seeking to reduce legal and reputational exposure to US legislation. By region, North America accounts for the largest market share. North America's endpoint security landscape is changing fast through strong collaborations between public and private organizations and technology partnerships between organizations, large and small, across Canada and the US. In Canada, Bell Canada partnered with SentinelOne to provide next-generation Managed Threat Detection and Response (MTDR) capabilities to its Security Operations Centre, while the University of Toronto gained 'next-gen' centralized threat management for nearly 10,000 endpoints across its campuses. In the US, federal funding and cooperation with industry partners facilitated programs including: Xage Security's USD 1.5 million contract with the US Navy to deliver Zero Trust Access as a multi-faceted and complex naval environment; and the White House combined with Microsoft and Google to deploy endpoint security capabilities, including training to critical rural hospitals. Additionally, Shepherd and Intel partnered to provide advanced Threat Detection Technology against ransomware threats. Together, all of the above describe the continent-wide approach toward advancing endpoint security through collaboration and investment and innovative platforms, aimed at addressing evolving cyber threats in all sectors, including healthcare, defense, academia, and enterprise. Key Attributes: Market Overview and Industry Trends Market Dynamics Drivers Restraints Opportunities Challenges Porter's Five Forces Analysis Value Chain Analysis Technology Analysis Impact of Generative AI on Endpoint Security Market Tariffs and Regulatory Landscape Competitive Landscape For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: SOFTWARE TECHNOLOGY INTERNET ARTIFICIAL INTELLIGENCE SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/21/2025 12:05 PM/DISC: 07/21/2025 12:05 PM
